INCYTE CORP
No SEC Form 4 filings for $INCY in the last 30 days.
See all $INCY insider activity →Incyte (INCY) will present new oncology data at ESMO 2026, including updates on KRAS G12D and TGFβR2×PD-1 programs. The data will inform ongoing Phase 3 studies, according to the company. An investor webcast is scheduled for October 26 to discuss the data and portfolio updates.
Incyte Corporation (Nasdaq: INCY) will release its third-quarter 2026 financial results on October 29, with a conference call and webcast scheduled for 8 a.m. Eastern Time. The company focuses on hematology, oncology, and inflammation treatments, and the earnings report will provide updates on its performance in these areas. Investors can access the call and replay via phone or webcast.
H.C. Wainwright reiterated a Buy rating and $152 price target for Incyte (INCY) after Verastem's KRAS G12D inhibitor data. INCB161734, Incyte's drug, showed 41% response rate in pancreatic cancer trials. INCY trades at P/E 14.5, PEG 0.18, with a $23B valuation. Multiple firms updated price targets recently.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning INCY (INCYTE CORP). Coverage has skewed bullish: 4 bullish, 2 neutral, and 1 bearish.
Recent INCY coverage spans financial news, earnings and technology.
The upcoming data could shift market expectations for Incyte's pipeline.
The earnings date announcement may generate modest pre‑market positioning as investors adjust expectations.
Positive trial data and higher price target suggest upside pressure on INCY.
Goldman Sachs lowered its price target for Incyte from $118 to $117. The stock is currently trading at $111.57, with a 5-day change of +2.72% and a year-to-date change of -1.65%. Truist also raised its target to $115 from $105, maintaining a Hold rating.
Hold rating with a higher target indicates upside potential.
AlphAI scores every news story that mentions INCY with an AI model for sentiment and relevance, and aggregates insider trades from INCYTE CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Incyte (INCY) will present new oncology data at ESMO 2026, including updates on KRAS G12D and TGFβR2×PD-1 programs. The data will inform ongoing Phase 3 studies, according to the company. An investor webcast is scheduled for October 26 to discuss the data and portfolio updates.
2 min readIncyte Corporation (Nasdaq: INCY) will release its third-quarter 2026 financial results on October 29, with a conference call and webcast scheduled for 8 a.m. Eastern Time. The company focuses on hematology, oncology, and inflammation treatments, and the earnings report will provide updates on its performance in these areas. Investors can access the call and replay via phone or webcast.
1 min readH.C. Wainwright reiterated a Buy rating and $152 price target for Incyte (INCY) after Verastem's KRAS G12D inhibitor data. INCB161734, Incyte's drug, showed 41% response rate in pancreatic cancer trials. INCY trades at P/E 14.5, PEG 0.18, with a $23B valuation. Multiple firms updated price targets recently.
2 min readGoldman Sachs lowered its price target for Incyte from $118 to $117. The stock is currently trading at $111.57, with a 5-day change of +2.72% and a year-to-date change of -1.65%. Truist also raised its target to $115 from $105, maintaining a Hold rating.
1 min readAnalysts from Barclays, Wells Fargo, and Chardan Capital provided ratings and price targets for 4D Molecular Therapeutics (FDMT), Pfizer (PFE), and Incyte (INCY). FDMT has a Strong Buy consensus with a $31.25 avg. target. PFE has a Moderate Buy consensus with a $29.62 avg. target. INCY has a Moderate Buy consensus with a $132.58 avg. target.
2 min readHC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.
1 min readGEN İlaç (GENIL) secured exclusive rights to market and distribute Incyte's Niktimvo in Türkiye and Opzelura in Türkiye and Azerbaijan under a five-year agreement. The deal aims to boost GEN's commercial growth and market position in advanced therapies.
2 min readIncyte's povorcitinib, an oral JAK inhibitor, showed efficacy in phase 3 trials for hidradenitis suppurativa (HS), with FDA review underway. Currently, 3 biologics (adalimumab, secukinumab, bimekizumab) are FDA-approved for HS. Dr. Jennifer Hsiao discusses treatment expectations, biologic selection, and the potential role of JAK inhibitors in HS management. Comorbidity screening is also emphasized in HS care.
3 min readBank of America Securities reiterated a Buy rating on Incyte (INCY) with a $140 price target. H.C. Wainwright also gave a Buy, while RBC Capital maintained a Hold. Incyte reported Q2 revenue of $1.67B and net profit of $585.61M, up from $1.22B and $405M last year. Insider sentiment is negative, with recent sales by executives.
1 min readIncyte (INCY) completed a Phase 1 study on oral povorcitinib and topical ruxolitinib cream, assessing drug movement and safety. The study, updated in October 2026, may support future trials and pipeline expansion in dermatology and immunology, though near-term revenue impact is uncertain.
1 min read
